[HTML][HTML] Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs

GJ Kontoghiorghes - International Journal of Molecular Sciences, 2023‏ - mdpi.com
The design of clinical protocols and the selection of drugs with appropriate posology are
critical parameters for therapeutic outcomes. Optimal therapeutic protocols could ideally be …

Functional genomics and insights into the pathogenesis and treatment of psoriasis

EM Shellard, SS Rane, S Eyre, RB Warren - Biomolecules, 2024‏ - mdpi.com
Psoriasis is a lifelong, systemic, immune mediated inflammatory skin condition, affecting 1–
3% of the world's population, with an impact on quality of life similar to diseases like cancer …

PDE4 Gene Family Variants Are Associated with Response to Apremilast Treatment in Psoriasis

K Liadaki, E Zafiriou, T Giannoulis, S Alexouda… - Genes, 2024‏ - mdpi.com
Moderate-to-severe psoriasis (Ps) treatment includes systemic drugs and biological agents.
Apremilast, a small molecule primarily metabolized by cytochrome CYP3A4, modulates the …

Paradoxical Psoriasis in Patients Receiving Therapy with Tumor Necrosis Factor Inhibitors: Potential Pathogenic Mechanisms and the Role of Genetic Factors

D Costin, AM Burlui, A Cardoneanu… - International Journal of …, 2024‏ - mdpi.com
TNF inhibitors (TNFi) have revolutionized the therapeutic management of various chronic
immune-mediated inflammatory diseases. Despite their known benefits, these therapies are …

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice

E Muñoz‐Aceituno, B Butrón‐Bris… - Journal of the …, 2024‏ - Wiley Online Library
Background Prediction of the response to a biological treatment in psoriasis patients would
allow efficient treatment allocation. Objective To identify polymorphisms associated with …

Integrating omics data for personalized medicine in treating psoriasis

M Ramchandani, AK Goyal - Medicinal Chemistry Research, 2024‏ - Springer
Psoriasis is a chronic, multifactorial skin disorder characterized by the hyperproliferation of
keratinocytes and persistent inflammation. It is driven by a complex interplay of genetic …

Treatment of Chronic Plaque Psoriasis: An Overview on Current Update

P Jurel, S Bahadur, M Bajpai - Pharmacological Research-Reports, 2024‏ - Elsevier
Introduction Chronic plaque psoriasis is an inflammatory skin disorder that affects 2% to 3%
of the population. The severity of the disease is influenced by the number and location of …

Polymorphisms of PDCD1 and COL9A1 Genes in Plaque, Palmoplantar and Arthropathic Psoriasis in Romanian Patients

DS Lupea-Chilom, SS Farcas, LC Popa, A Tudor… - Applied Sciences, 2024‏ - mdpi.com
In recent years, genetic studies have brought new insights into psoriasis, a chronic
inflammatory disease with multiple determining and favoring factors. Recent advances in the …

[HTML][HTML] The new era of immune skin diseases: Exploring advances in basic research and clinical translations

B Zhang, X Mei, M Zhao, Q Lu - Journal of Translational Autoimmunity, 2024‏ - Elsevier
As a vital immune organ, skin performs multiple physiological functions. Immune skin
diseases (ISDs) arecharacterized by dysregulated immune responses, manifested as …

Psoriasis-Interactions Between Genetic Susceptibility, Bacterial Microbiome, and Gene Expression

M Assarsson - 2024‏ - diva-portal.org
Psoriasis is a common immune-mediated inflammatory disease, caused by a combination of
genetic predisposition and environmental trigger factors. In spite of extensive research …